CEL-SCI to Present at 13th Annual BIO CEO & Investor Conference

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE AMEX:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2011 BIO CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). The conference will take place February 14-15 at the Waldorf-Astoria in New York.

Mr. Kersten’s presentation will be on Tuesday, February 15th, at 9:30 a.m. The presentation will be webcast live with a slide presentation and archived until May 16, 2011. The webcast can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2011/28204257.cfm.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product, Multikine®, is currently being tested in a global Phase III clinical trial that started in December 2010. In Phase II clinical trials Multikine was shown to be safe and well-tolerated and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery.

CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.



CONTACT:

CEL-SCI Corporation
Gavin de Windt, 703-506-9460
www.cel-sci.com

KEYWORDS:   United States  North America  New York  Virginia

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Infectious Diseases  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.